Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Myeloid Leukemia
60%
Diffuse Large B-cell Lymphoma (DLBCL)
44%
Myelodysplastic Syndrome
36%
Relapsed or Refractory
35%
Overall Survival
31%
Confidence Interval
27%
Rituximab
27%
Decitabine
25%
Lymphoma Patients
25%
Mantle Cell Lymphoma
25%
Phase II Study
24%
Granulocyte Colony-stimulating Factor (G-CSF)
24%
Plerixafor
23%
Natural Killer Cells
19%
Follicular Lymphoma
19%
Progression-free Survival
19%
Complete Remission
19%
Chemotherapy
18%
Cytarabine
18%
Autologous Transplantation
17%
Azacitidine
16%
Lenalidomide
16%
Relapsed Lymphoma
16%
Leukemia
16%
Lymphoma
15%
Hodgkin Lymphoma
15%
Older Patients
15%
Graft-versus-host Disease (GvHD)
14%
Relapsed or Refractory Acute Myeloid Leukemia
14%
Hazard Ratio
13%
Stem Cells
12%
Phase I Study
12%
Overall Response Rate
12%
Stem Cell Mobilization
11%
Interleukin-15 (IL-15)
11%
Hematopoietic Cell Transplantation
11%
Unrelated Donor
11%
Memory-like
11%
Leukemia Patients
11%
Classical Hodgkin Lymphoma
11%
Conditioning Regimen
10%
Cyclophosphamide
9%
Myeloablative Conditioning
9%
Reduced-intensity Conditioning
9%
Hypomethylating Agents
9%
Chronic Lymphocytic Leukemia
9%
B-cell Lymphoma
9%
Allogeneic Transplantation
9%
Maintenance Therapy
9%
Medicine and Dentistry
Hematopoietic Cell
54%
Acute Myeloid Leukemia
49%
Cell Transplantation
46%
Diffuse Large B-Cell Lymphoma
35%
Transplantation
34%
Overall Survival
33%
Mantle Cell Lymphoma
21%
Plerixafor
21%
Rituximab
21%
Chemotherapy
20%
Myelodysplastic Syndrome
20%
Neoplasm
19%
Natural Killer Cell
18%
Hodgkin's Lymphoma
18%
Decitabine
17%
Progression Free Survival
15%
Azacitidine
14%
Classical Hodgkin Lymphoma
14%
Granulocyte Colony Stimulating Factor
13%
Leukemia
13%
Stem Cell Transplant
12%
Autologous Stem Cell Transplantation
12%
Allogeneic Stem Cell Transplantation
11%
Stem Cell
11%
Disease
11%
Hematopoietic Stem Cell Transplantation
11%
Lenalidomide
11%
Follicular Lymphoma
11%
Cytarabine
10%
Hazard Ratio
10%
Autotransplantation
10%
Malignant Neoplasm
9%
Clinical Trial
9%
Graft Versus Host Reaction
9%
Cell Therapy
9%
Positron Emission Tomography-Computed Tomography
8%
Bendamustine
8%
Chemokine Receptor CXCR4 Antagonist
8%
Stem Cell Mobilization
8%
Conditioning
7%
T Cell
7%
Reduced Intensity Conditioning
7%
Polyethylene Terephthalate
7%
Allograft
7%
Myeloablative Conditioning
7%
Hypomethylating Agent
7%
Non-Hodgkin Lymphoma
7%
Maintenance Therapy
6%
Lymphoma Cell
6%
Interleukin 15
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
48%
Myelodysplastic Syndrome
35%
Decitabine
23%
Remission
23%
Diffuse Large B Cell Lymphoma
19%
Plerixafor
19%
Rituximab
18%
Azacitidine
17%
Lenalidomide
16%
Overall Survival
15%
Cytarabine
15%
Progression Free Survival
14%
Granulocyte Colony Stimulating Factor
13%
Follicular Lymphoma
10%
Mantle Cell Lymphoma
10%
Neoplasm
9%
Bendamustine
9%
Disease
9%
Chemotherapy
9%
Polyethylene Terephthalate
8%
Chronic Lymphatic Leukemia
8%
Belinostat
8%
Cyclophosphamide
8%
Maximum Tolerated Dose
7%
Graft Versus Host Reaction
6%
Clinical Trial
6%
Multiple Myeloma
6%
Nonhodgkin Lymphoma
6%
Pharmacokinetics
6%
Fludarabine
6%
Adverse Event
6%
Tolerability
5%
Classical Hodgkin Lymphoma
5%
Peripheral T Cell Lymphoma
5%
Chemokine Receptor CXCR4 Antagonist
5%
Clofarabine
5%